2021 年 9 月 21 日肝脂肪变性在 HBeAg 阴性慢性乙型肝炎患者 HBs

StephenW

国际医学会临床实践. 2021 年 9 月 21 日；e14899。doi：10.1111/ijcp.14899。印刷前在线。肝脂肪变性在 HBeAg 阴性慢性乙型肝炎患者 HBsAg 血清学转换中的作用Ferhat Bacaksız 1 , Hale Gökcan 1 , Meral Akdoğan 1 , Dilara Turan Gökçe 1 , Derya Arı 1 , Volkan Gökbulut 1 , Yakup Ergün 2 , Ömer Öztürk 1 , Sabite Kacar 1隶属关系    PMID：34547163 DOI：10.1111/ijcp.14899抽象的背景：在慢性 HBV 感染中，某些个体和病毒特征如高龄、存在肝脂肪变性 (HS)、正常 ALT 水平、最初阴性的 HBeAg 和 HBV DNA 以及病毒的基因型与 HBsAg 血清清除和血清转换有关。在此，我们报告了评估肝脂肪变性和 HbsAg 血清学转换之间关联的研究结果。方法：评估慢性乙型肝炎合并肝脂肪变性（HS）患者（HBsAg血清转换，n：52，非HbsAg血清转换，n：352）的临床和生化资料，以及HBsAg血清转换的发生率。结果：我们收集了 404 名 HBeAg 阴性 CBH 患者的数据（平均年龄 ± SD：36.2±11 岁；223 名 [55.2%] 男性，181 名 [44.8 %] 女性）。诊断疾病时的平均年龄为 36.2 ± 11 岁。该病的平均持续时间为 10.6±7 年。血清 HBsAg 阳性的 52 名患者 (12.8%) 发生血清转换（平均值±标准差：12.7±5.8）。高龄和疾病持续时间与血清转化显着相关（p<0.001）。血清 HBsAg 血清学转换的存在与肝脂肪变性显着相关（OR：3.06，95% CI 1.64-5.71，p <0.01）。与中重度 HS 患者相比，轻度 HS 患者的血清 HBsAg 血清学转换更频繁（p=0.04）。在多元回归分析中，发现 HS 的存在是预测 HBsAg 血清学转换发展的独立因素（OR：2.07 95% GA：1.07-4.0 p=0.03）。结论：HBeAg 阴性慢性乙型肝炎患者轻度 HS 的存在有助于 HBsAg 血清学转换。需要进一步研究以更好地了解脂肪变性与 HBsAg 血清学转换之间的关系。关键词：HBsAg 携带者；肝脂肪变性;血清清除；血清转化。本文受版权保护。版权所有。

StephenW

Int J Clin Pract

. 2021 Sep 21;e14899.
doi: 10.1111/ijcp.14899. Online ahead of print.
Role of hepatosteatosis in HBsAg seroconversion in HBeAg-negative chronic hepatitis B patients
Ferhat Bacaksız  1 , Hale Gökcan  1 , Meral Akdoğan  1 , Dilara Turan Gökçe  1 , Derya Arı  1 , Volkan Gökbulut  1 , Yakup Ergün  2 , Ömer Öztürk  1 , Sabite Kacar  1
Affiliations

    PMID: 34547163 DOI: 10.1111/ijcp.14899

Abstract

Background: In chronic HBV infection, certain individual and viral characteristics such as advanced age, presence of hepatic steatosis (HS), normal ALT levels, initially negative HBeAg and HBV DNA, and genotype of the virus are associated with HBsAg seroclearance and seroconversion. Herein, we report the results of our study evaluating the association between hepatosteatosis and HbsAg seroconversion.

Methods: The clinical and biochemical data of patients with CHB and hepatosteatosis (HS) (HBsAg seroconversion, n:52, and non-HbsAg seroconversion, n:352), and the rate of development HBsAg seroconversion were evaluated.

Results: We collected data from 404 patients with HBeAg negative CBH (mean age ± SD: 36.2±11 years; 223 [55.2%] men, 181 [44.8 %] women). The mean age at diagnosis of disease was 36.2 ± 11 years. The mean duration of the disease was 10.6±7 years. Seroconversion developed in 52 patients (12.8%) with serum HBsAg positive (mean ± SD: 12.7±5.8). Elderly age and the duration of disease time were significantly associated with seroconversion (p<0.001). The presence of serum HBsAg seroconversion was significantly associated with hepatosteatosis (OR: 3.06, 95% CI 1.64-5.71, p <0.01). Serum HBsAg seroconversion was more frequent in patients with mild HS than patients with moderate-severe HS (p=0.04). In multivariate regression analysis, the presence of HS was found to be an independent factor predicting the development of HBsAg seroconversion (OR: 2.07 95% GA:1.07-4.0 p=0.03).

Conclusion: The presence of mild HS in HBeAg negative chronic hepatitis B patients contributes to HBsAg seroconversion. Further studies are required to better understand the relationship between steatosis and HBsAg seroconversion.

Keywords: HBsAg carriers; Hepatic steatosis; Seroclearance; Seroconversion.

This article is protected by copyright. All rights reserved.

StephenW

其他地方也报道了类似的结果。
它可能不适用于出生时感染HBV 患者 或 依赖于 HBV 的基因型.